Zetia Sales Data

Rank 28 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Zetia U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 28 4.04% -3.33%
Q3 2013 28 (1) 7.25% -1.81%
Q2 2013 29 (2) 0.89% -0.30%
Q1 2013 31 (1) 5.27% 0.86%
Q4 2012 32 (4) 4.04% 1.33%
Q3 2012 36 (7) 7.06% 1.72%
Q2 2012 43 (3) 2.52% -1.69%
Q1 2012 46 2.67% 0.41%
Q4 2011 46 (2) 2.80% -0.10%
Q3 2011 44 (4) -7.20% -4.00%
Q2 2011 40 (2) 1.10% -0.10%
Q1 2011 42

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
November 16, 2009Study Raises New Questions About Merck Pill Zetia
November 15, 2009New Study Raises New Questions About Cholesterol Drug Zetia
January 9, 2009Update of Safety Review Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor)
August 22, 2008FDA Issues Early Communication About Ongoing Safety Review of Vytorin,  Zocor and Zetia
Hide
(web2)